title: Unusual presentation of Ewing sarcoma in the adrenal gland: a secondary malignancy from a survivor of Burkitt lymphoma.
abstract: The occurrence of Ewing sarcoma as a secondary malignancy is an extremely rare event in long-term cancer survivors. In addition, the occurrence of Ewing sarcoma in the adrenal gland is highly unusual. In this case report, we treated a 20-year-old male patient with cyclophosphamide, doxorubicin, vincristine, dexamethasone, and methotrexate and cytarabine chemotherapy following a diagnosis of Stage IV Burkitt lymphoma. Following complete remission, he had been maintained for 2 years without evidence of disease. However, a regular follow-up computed tomography scan found a left adrenal gland mass and a biopsy revealed positive membrane-localized mic-2 expression (CD99) and the presence of the translocation of the EWSR1 gene. To our knowledge, this is the first case report of Ewing sarcoma occurring in the adrenal gland of a patient who was treated with cyclophosphamide, doxorubicin, vincristine, dexamethasone/methotrexate and cytarabine chemotherapy for Burkitt lymphoma.
authors.affiliation: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong Gangnam-gu, Seoul 135-710, Korea.
authors.forename: Sung Hee
authors.initials: SH
authors.lastname: Lim
authors.forename: Ji Yoon
authors.initials: JY
authors.lastname: Lee
authors.forename: Ji Young
authors.initials: JY
authors.lastname: Lee
authors.forename: Ji Hoon
authors.initials: JH
authors.lastname: Kim
authors.forename: Ki Hong
authors.initials: KH
authors.lastname: Choi
authors.forename: Ji Yeon
authors.initials: JY
authors.lastname: Hyun
authors.forename: Young Hyeh
authors.initials: YH
authors.lastname: Ko
authors.forename: Jeeyun
authors.initials: J
authors.lastname: Lee
authors.forename: Seok Jin
authors.initials: SJ
authors.lastname: Kim
authors.forename: Won Seok
authors.initials: WS
authors.lastname: Kim
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000473:pathology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002051:Burkitt Lymphoma / Q000188:drug therapy* / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D012512:Sarcoma, Ewing / Q000473:pathology*; D055815:Young Adult
chemical_list: D003561:Cytarabine; D004317:Doxorubicin; D003520:Cyclophosphamide; D007069:Ifosfamide; D011241:Prednisone; D008727:Methotrexate
keywords: Burkitt lymphoma; Ewing sarcoma; secondary malignancy